Veracyte | VCYT - Gross Profit On Sales

Stock Price
37.22
Daily Change
-1.53 -3.95%
Monthly
-3.27%
Yearly
7.08%
Q1 Forecast
34.53

Veracyte reported $101.97M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
Agenus USD 23.93M 2.79M Mar/2025
Agilent USD 946M 44M Dec/2025
Anika Therapeutics USD 14.68M 9.46M Mar/2025
Arrowhead Research USD 256.47M 228.7M Sep/2025
Bruker USD 449.2M 69.8M Dec/2025
Exact Sciences USD 583.93M 21.48M Sep/2025
Heron Therapeutics USD 23.35M 1.6M Sep/2024
Illumina USD 759M 26M Dec/2025
Intrexon USD -297K 167K Jun/2024
Karyopharm Therapeutics USD -30.78M 1.29M Dec/2024
Laboratory Of America USD 993.2M 31.9M Dec/2025
Ligand Pharmaceuticals USD 155.28M 82.42M Sep/2025
Myriad Genetics USD 143.8M 8M Sep/2025
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Roche Holding CHF 22.09B 10.04B Dec/2025
Sangamo BioSciences -2.39M 1.09M Jun/2024
Siemens EUR 8.1B 567M Sep/2025
Sonic Healthcare AUD 3.92B 3.14B Dec/2024
Thermo Fisher Scientific USD 4.64B 419M Dec/2025
Veracyte USD 101.97M 10.69M Dec/2025
Waters USD 557.42M 97.44M Dec/2025